Health-Related Quality of Life (HRQoL), in Patients With Durable Response to Immune Checkpoint Inhibitors (ICIS) for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma: QUALICI Study

Speaker(s)

Girard N1, Robert C2, Spurrier G3, Lemasson H4, Chartier M5, Moreau-Mallet V6, Micheliza S7, Texier N8, Hervy S8, Coint-Bavarot M8, Bonastre J9
1Institut Curie, Institut Mutualiste Montsouris, Paris, Ile de France, France, 2Gustave Roussy and Paris Saclay University, Villejuif, Ile de France, France, 3Melanome France, Teilhet, Auvergne Rhône Alpes, France, 4Bristol-Myers Squibb, RUEIL MALMAISON, France, 5Bristol Myers Squibb, Rueil Malmaison, France, 6Bristol Myers Squibb, Rueil-Malmaison, Ile de France, France, 7Bristol Myers Squibb, Rueil Malmaison, Ile de France, France, 8Kappa Santé, paris, Ile de France, France, 9Institut Gustave Roussy Cancer Campus, Villejuif, France

Presentation Documents

OBJECTIVES:

With ICIS, the prognosis of advanced forms of cancer including melanoma (Mel) and NSCLC has significantly improved and has led to the emergence of a new population of patients with durable response to ICIs (ICI-DR). These patients face specific HRQoL issues, which implies a better knowledge of their experience and needs. QUALICI study aimed to provide an overview of these patients’ quality of life, of their experiences and expectations regarding their HRQoL management.

METHODS:

All patients with ICI-DR, defined as ICIs started for ≥2 years without subsequent treatment, were screened in the 16 French participating sites and randomly selected to participate in this cross-sectional study. Participants completed questionnaires including the EQ-5D-5L, the Chalder Fatigue Scale (CFQ-11) and the Social Difficulties Inventory (SDI).

RESULTS:

The 234 participating patients (117 Mel; 117 NSCLC), had a mean ICI-DR of 48.8 (±14.5) months. Of them, 74.8% initiated ICI at metastatic stage and 29,5% (22.2% Mel and 36.8% NSCLC) were still receiving ICI.

Most patients (NSCLC ≥62%; Mel ≥69.7%) reported no or slight problems on the 5 EQ-5D-5L dimensions. Mean EQ-5D-5L Index Utility Score were 0.9 (±0.1) and 0.87 (±0.2) and Visual Analogic Scores 74.8 (±19) and 67.0 (±19.3) in Mel and NSCLC patients, respectively.

Mean CFQ-11 scores were 13.8 (±4.5) (Mel) and 15.5 (± 5.7) (NSCLC). Proportions of patients with moderate/ severe fatigue were 84.0%/ 4.7% and 68.3%/ 21.2% in Mel and NSCLC patients, respectively.

Total SDI scores were 5.9 (± 6.6) (Mel) and 10.4 (±8.5) (NSCLC) with 25% and 50% of Mel and NSCLC patients identified as having difficulties (score ≥10).

CONCLUSIONS: Patients with ICI-DR had an overall satisfying HR-QoL although EQ-5D-5L assessments remained below those of the general population of their age. A few of them particularly among NSCLC ICI-DR patients experienced significant QoL issues, which would require a specific management.

Code

PCR218

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Drugs, Oncology